PlantForm
PlantForm Corporation is a Canadian biopharmaceutical company that uses its proprietary vivoXPRESS® plant-based manufacturing platform to produce biosimilar antibodies, medical countermeasures, and animal health products at significantly lower cost than mammalian cell systems.
- Company typePrivate
- Founded2008
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What PlantForm does
PlantForm Corporation is a privately-held Canadian biopharmaceutical company founded in 2008 that develops and manufactures biologic drugs using a proprietary plant-based expression platform called vivoXPRESS®. The platform uses genetically modified Nicotiana benthamiana (tobacco) plants as bioreactors to produce monoclonal antibodies, therapeutic proteins, and vaccines, with company-claimed manufacturing cost reductions of up to 90% and development timelines as short as six weeks versus traditional mammalian cell systems. The company's intellectual property is protected by seven patent families with seven issued or allowed patents covering the core platform, glycosylation engineering, and product-specific applications. Its pipeline spans biosimilar versions of Keytruda® (pembrolizumab), Lucentis® (ranibizumab), and Herceptin® (trastuzumab); medical countermeasures including an anti-ricin antibody (hD9) and recombinant butyrylcholinesterase (BuChE) for nerve agent protection; animal health products such as a PEDv vaccine, E. coli antibody feed additive, and avian influenza H5/H7 antigens; and emerging programs in recombinant human collagen and plant-made artificial exosomes.
The company serves three primary customer categories: government defense and biodefense agencies (Defence Research and Development Canada, USAMRIID, NRC-IRAP), pharmaceutical and biotech firms seeking low-cost biosimilar production, and contract development and manufacturing (CDMO) clients. Revenue mechanics combine non-dilutive government grants and contracts, technology licensing, joint ventures (notably the PlantPraxis JV in Brazil with PharmaPraxis/Axis Biotec Brasil), biosimilar co-development arrangements, and CDMO service fees. The company operates two Canadian sites—a headquarters at 1920 Yonge Street in Toronto and an R&D facility at The Research Park in Sarnia, Ontario—with an employee count of 11–50 and active collaborations extending into Brazil, South Africa, Thailand, and South Korea.
PlantForm firmographics
Firmographics- Name
- PlantForm
- Legal name
- PlantForm Corporation
- Website
- https://plantformcorp.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PlantForm Corporation is a Canadian biopharmaceutical company that uses its proprietary vivoXPRESS® plant-based manufacturing platform to produce biosimilar antibodies, medical countermeasures, and animal health products at significantly lower cost than mammalian cell systems.
- Ownership category
- akta.pro rank
PlantForm industry classification
Industry- Product category
- Biopharmaceutical Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where PlantForm is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
PlantForm business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- CDMO Services: Contract Development and Manufacturing Organization services offering the vivoXPRESS® platform to other parties for production of antibodies and proteins under contract arrangements.
- Technology Licensing: Licensing arrangements for use of proprietary plant-based manufacturing platform technology.
- Government Contracts: Funding and contracts from government agencies including Defence Research and Development Canada, USAMRIID, and NRC-IRAP for development of medical countermeasures and therapeutics.
- Biosimilar Drug Development: Development and potential commercialization of biosimilar versions of approved biologic drugs including Keytruda, Lucentis, and other niche indication drugs.
- Joint Ventures: Revenue through joint ventures such as PlantPraxis (with PharmaPraxis/Axis Biotec Brasil) for development and commercialization of biosimilars for specific markets like Brazil.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
PlantForm product offering
Product offeringCore offering
PlantForm Corporation develops and commercializes the proprietary vivoXPRESS® plant-based biopharmaceutical manufacturing platform, which uses genetically modified Nicotiana (tobacco) plants as bioreactors to produce monoclonal antibodies, therapeutic proteins, and vaccines. The company also offers Contract Development and Manufacturing Organization (CDMO) services, biosimilar drug candidates (Keytruda, Lucentis, Herceptin biosimilars), medical countermeasures (anti-ricin antibody, BuChE), and animal health products using this platform.
Product overview
PlantForm Corporation is a biopharmaceutical company offering the proprietary vivoXPRESS® plant-based manufacturing platform for low-cost, rapid production of biologics including monoclonal antibodies, therapeutic proteins, and vaccines. The company's portfolio consists of: (1) the core vivoXPRESS® platform for plant-based expression in Nicotiana plants; (2) a pipeline of biosimilar drug candidates including Keytruda® (pembrolizumab), Lucentis® (ranibizumab), and Herceptin® (trastuzumab) for cancer and eye disease treatment; (3) medical countermeasures including anti-ricin antibody antidote and butyrylcholinesterase (BuChE) for nerve agent protection; (4) animal health products including PEDv vaccine and E. coli antibody feed additives; and (5) CDMO contract manufacturing services. Recent collaborations include avian influenza antigen production and artificial exosome development for therapeutics.
Differentiator
Problem solved
Functional benefit
Brands
- vivoXPRESS®: Proprietary plant-based biopharmaceutical manufacturing platform technology that produces biologic drugs in tobacco plants at significantly reduced cost compared to mammalian cell systems.
Products and services
- vivoXPRESS® Platform Proprietary plant-based biopharmaceutical manufacturing platform that enables rapid development and production of specialty antibody and protein drugs using genetically modified tobacco plants (Nicotiana sp.), offering faster timelines (as little as six weeks), lower costs (up to 90% reduction), and scalable production with mammalian glycosylation.
- CDMO Services Contract Development and Manufacturing Organization services offering the vivoXPRESS® technology platform to other parties for production of antibodies and proteins under contract and licensing arrangements.
- Ricin Antidote (Anti-ricin antibody hD9) Innovative plant-made antidote to ricin exposure developed using the vivoXPRESS® platform, with testing conducted in collaboration with Defence Research and Development Canada (DRDC) and USAMRIID.
- Biosimilar Pembrolizumab (Keytruda®) Biosimilar version of Keytruda® (pembrolizumab) for cancer treatment, being developed under collaboration with Bio-Manguinhos/Fiocruz in Brazil for the Latin American market.
- Biosimilar Ranibizumab (Lucentis®) Biosimilar version of Lucentis® (ranibizumab) for eye disease treatment, being developed for niche indication markets.
- Biosimilar Trastuzumab (Herceptin®) Biosimilar version of Herceptin® (trastuzumab) for breast cancer treatment, demonstrated comparable efficacy to originator in mouse studies.
- Recombinant Butyrylcholinesterase (BuChE) Plant-produced enzyme developed as a bioscavenger for prophylactic protection against nerve agents such as sarin gas, with ongoing research for sialylated versions to improve pharmacokinetics.
- Avian Influenza Antigens (H5 and H7) Plant-based produced avian influenza H5 and H7 antigens for diagnostic testing, being developed in collaboration with Smart Biotech for commercial bird operations in South Africa.
- Porcine Epidemic Diarrhea Virus (PEDv) Vaccine Vaccine candidate to prevent Porcine Epidemic Diarrhea Virus infections in pigs, developed in collaboration with Agriculture and Agri-Food Canada (AAFC).
- E. coli Antibody (Feed Additive) Antibody feed additive to prevent E. coli infections in pigs, developed to improve livestock health and human food safety.
- Recombinant Human Collagen Plant-based recombinant human collagen using synthetic biology via the vivoXPRESS® platform for scalable production of properly hydroxylated human collagen in plants, targeting various markets including biomedical and cosmetics.
Quantifiable outcome
- Manufacturing cost reduction of up to 90% compared to mammalian cell systems
- +2 more outcomes
Companies that use PlantForm
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
PlantForm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
PlantForm partnerships and signals
Strategic signalPartnerships
23 partnerships are on record, tiered core and minor.
- Baiya Phytopharm Co. Ltd.coreThree-way collaboration with The DABOM to develop plant-made artificial exosomes for therapeutics and drug delivery. PlantForm designs and synthesizes CD9 gene using vivoXPRESS platform. Baiya expresses and purifies recombinant CD9 in N. benthamiana plants using BaiyaPharming platform. Project aims to overcome scalability barriers in artificial exosome production.
- The DABOM Inc.coreKorean company using AI and microfluidics for mass production of artificial exosomes. Part of three-way collaboration to develop exosomes for cancer and neurodegenerative disease treatments. The DABOM produces artificial exosomes and compares them to natural exosomes.
- Smart BiotechcoreResearch project to evaluate plant-based production of avian influenza H5 and H7 antigens for diagnostic test kit development. PlantForm will use vivoXPRESS platform to express antigens for commercial bird operations in South Africa. Project addresses need for diagnostic tests that can distinguish vaccinated from infected birds.
- Agriculture and Agri-Food Canada (AAFC)minorResearch funding to develop vaccine for porcine epidemic diarrhea virus (PEDv) and E. coli infections in pigs.
- 3DBioFibRminorNGen funding collaboration to advance recombinant human collagen fiber manufacturing technology.
- SwiftPharmacoreGlobal licensing agreement and contract manufacturing agreement for plant-made biosimilars targeting blockbuster cancer drugs.
- AntoXa CorporationcoreExclusive collaboration for development and commercialization of plant-made antibody against ricin exposure. AntoXa received Defence R&D Canada license for anti-ricin antibody technology.
- Bio-Manguinhos/FiocruzcoreAgreement to develop biosimilar pembrolizumab cancer drug and additional products for Brazilian market.
- Cape Biologix TechnologiesminorAgreement to commercialize COVID-19 antibody blood test.
- Inno-3BminorAgreement to commercialize COVID-19 antibody blood test.
- South Africa's CSIRminorResearch collaboration with BGM Pharmaceuticals for plant-based protein production.
- McMaster UniversityminorNSERC Engage Grant research collaboration.
- University of Guelph (GlycoNet)minorGlycoNet grant for research partnership.
- University of CalgaryminorNSERC Engage Grant research collaboration.
- University of New MexicominorFiloviridae glycoprotein project collaboration.
- Université de Montréal (Dr. Andrés Finzi)minorCollaboration on HIV antibody elimination assays to determine efficacy of plant-based antibody cocktails for killing infected CD4+ T cells.
- Axis Biotec Brasil / PharmaPraxiscoreJoint venture (PlantPraxis) established to develop, manufacture, and commercialize biosimilar and biobetter versions of key biologic drugs for Brazilian market. Received US$1 million Finep grant for Humira biosimilar development and pilot manufacturing facility.
- University of Guelph (CESRF)coreNSERC Collaborative Research and Development Grant ($300K from NSERC, $378K from PlantForm) to optimize plant production of therapeutic antibodies. Three-year project with Dr. Mike Dixon's Controlled Environment Systems Research Facility.
- Defence Research and Development Canada (DRDC)coreGovernment contract for plant-based production of anti-ricin antibody (hD9). DRDC conducted in vitro and in vivo studies showing plant-made antibody efficacy comparable to mammalian-produced version.
- Ryerson University (Dr. Warren Wakarchuk)minorCollaboration on sialylation of plant-made BuChE for optimal bloodstream activity.
- University of CalgaryminorNSERC Engage Grant to assess CRISPR technology for improving tobacco-plant production of therapeutic proteins with Dr. Dae-Kyun Ro.
- Miami Mice Research CorpminorCollaboration to develop innovative mouse model for testing HIV antibodies.
- U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)coreCooperative Research and Development Agreement for production and testing of Ebola Sudan antibodies using PlantForm's vivoXPRESS system. USAMRIID provides amino acid sequences and conducts evaluation of resulting material.
Scale indicators11 records
Recent moves9 records
Expansion highlights5 records
PlantForm competitors and assessment
Company assessmentEmerging players
- Mapp Biopharmaceutical: US biopharma focused on antibody-based countermeasures against infectious disease and biothreats — comparable to PlantForm's anti-ricin hD9, Ebola Sudan, and BuChE medical countermeasure programs and biodefense customer relationships.
- Leaf Expression Systems: UK-based plant expression company offering transient expression services in Nicotiana benthamiana — directly comparable plant-based CDMO/protein production technology to vivoXPRESS®, with overlapping academic and pharma client base.
- Cape Biologix Technologies: South African plant-based protein expression company developing diagnostics and reagents using Nicotiana — comparable to PlantForm's avian influenza antigen and COVID-19 antibody test work, but focused on diagnostic rather than therapeutic applications.
Broad incumbents
- Lonza Biologics: Global leader in mammalian-cell-based contract biologics manufacturing — represents the established incumbent CDMO benchmark against which PlantForm's plant-based CDMO must compete for pharma contract manufacturing work.
- Bio-Manguinhos / Fiocruz: Brazilian public-sector biopharmaceutical manufacturer partnered with PlantForm on biosimilar pembrolizumab — a strategic collaborator and broader incumbent in Latin American biologics manufacturing with similar biosimilar development mission.
Direct peers
- Kentucky BioProcessing (KBP): Plant-based protein and vaccine CDMO owned by British American Tobacco, using tobacco-plant expression for rapid biologics production — a direct competitor in plant-made pharmaceuticals with overlapping government/biodefense work.
- Medicago: Canadian biopharmaceutical company that uses Nicotiana-based plant expression to produce vaccines and therapeutic proteins — the closest direct peer to PlantForm's vivoXPRESS® platform, both in core technology and in government/defense customer focus.
- Protalix BioTherapeutics: Plant-cell-based biopharmaceutical company (using carrot cell bioreactors, ProCellEx) developing approved biologic drugs — shares the plant-based biologics development and commercial model with PlantForm, though using cell suspension rather than whole-plant systems.
- iBio: US-based plant-based biopharmaceutical CDMO offering contract manufacturing of proteins and antibodies using a proprietary plant expression platform — directly comparable to PlantForm's CDMO services and biologics pipeline.
- Baiya Phytopharm: Thailand-based company using Nicotiana benthamiana (BaiyaPharming) plant-based expression to produce therapeutic proteins — an active PlantForm collaborator and direct peer in plant-made biologics for emerging-market applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
PlantForm social profiles
Digital presencePlantForm financial estimates
Financial estimateRevenue estimate
Valuation estimate
PlantForm leadership team
Management profileNumber of profiles
Profiles6 records
PlantForm subsidiaries and ownership
Company hierarchySubsidiaries1 record
PlantForm funding detail
Funding detailFunding overview
Funding rounds7 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PlantForm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PlantForm
What does PlantForm do?
PlantForm Corporation develops and commercializes the proprietary vivoXPRESS® plant-based biopharmaceutical manufacturing platform, which uses genetically modified Nicotiana (tobacco) plants as bioreactors to produce monoclonal antibodies, therapeutic proteins, and vaccines. The company also offers Contract Development and Manufacturing Organization (CDMO) services, biosimilar drug candidates (Keytruda, Lucentis, Herceptin biosimilars), medical countermeasures (anti-ricin antibody, BuChE), and animal health products using this platform.
Is PlantForm a public or private company?
PlantForm is a private company. It is classified as venture growth investor backed and is currently operating.
When was PlantForm founded?
PlantForm was founded in 2008. It employs 11 to 50 people.
Where is PlantForm based?
PlantForm is headquartered in Toronto, Canada, in the North America region.
How does PlantForm make money?
Five revenue lines are on record. CDMO Services are the primary driver. The others are technology Licensing, government Contracts, biosimilar Drug Development and joint Ventures.
Who are PlantForm's main competitors?
Emerging players on record are Mapp Biopharmaceutical, Leaf Expression Systems and Cape Biologix Technologies. Broad incumbents are Lonza Biologics and Bio-Manguinhos / Fiocruz. Direct peers are Kentucky BioProcessing (KBP), Medicago, Protalix BioTherapeutics, iBio and Baiya Phytopharm.
Does PlantForm have an API?
No public API is recorded for PlantForm.
What industry is PlantForm in?
PlantForm's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 8731.